{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:30:12Z","timestamp":1791282612568,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2010,6,16]],"date-time":"2010-06-16T00:00:00Z","timestamp":1276646400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1007\/s00228-010-0847-9","type":"journal-article","created":{"date-parts":[[2010,6,15]],"date-time":"2010-06-15T09:35:24Z","timestamp":1276594524000},"page":"1017-1023","source":"Crossref","is-referenced-by-count":23,"title":["Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children"],"prefix":"10.1007","volume":"66","author":[{"given":"Doaa","family":"Elsherbiny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"McIlleron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Maartens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrika S. H.","family":"Simonsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,6,16]]},"reference":[{"key":"847_CR1","first-page":"672","volume":"6","author":"PM Jeena","year":"2002","unstructured":"Jeena PM, Pillay P, Pillay T, Coovadia HM (2002) Impact of HIV-1 co-infection on presentation and hospital-related mortality in children with culture proven pulmonary tuberculosis in Durban, South Africa. Int J Tuberc Lung Dis 6:672\u2013678","journal-title":"Int J Tuberc Lung Dis"},{"key":"847_CR2","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1086\/501018","volume":"42","author":"SD Lawn","year":"2006","unstructured":"Lawn SD, Bekker LG, Middelkoop K, Myer L, Wood R (2006) Impact of HIV infection on the epidemiology of tuberculosis in a peri-urban community in South Africa: the need for age-specific interventions. Clin Infect Dis 42:1040\u20131047","journal-title":"Clin Infect Dis"},{"key":"847_CR3","unstructured":"Lopinavir\/ritonavir (Kaletra) [package insert]. Abbott Laboratories, Chicago"},{"key":"847_CR4","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1055-3290(06)60137-4","volume":"12","author":"DJ Porche","year":"2001","unstructured":"Porche DJ (2001) Lopinavir\/ritonavir. J Assoc Nurses AIDS Care 12:101\u2013104","journal-title":"J Assoc Nurses AIDS Care"},{"key":"847_CR5","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/sj.clpt.6100027","volume":"81","author":"GW Hogeland","year":"2007","unstructured":"Hogeland GW, Swindells S, McNabb JC, Kashuba AD, Yee GC, Lindley CM (2007) Lopinavir\/ritonavir reduces bupropion plasma concentrations in healthy subjects. Clin Pharmacol Ther 81:69\u201375","journal-title":"Clin Pharmacol Ther"},{"key":"847_CR6","unstructured":"WHO (2006) Guidance for National Tuberculosis Programmes on the management of tuberculosis in children. Available from: http:\/\/www.who.int\/child-adolescent-health\/New_Publications\/CHILD_HEALTH\/WHO_FCH_CAH_2006.7.pdf . Accessed October 2009"},{"key":"847_CR7","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0022-3565(24)29202-8","volume":"299","author":"JM Rae","year":"2001","unstructured":"Rae JM, Johnson MD, Lippman ME, Flockhart DA (2001) Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther 299:849\u2013857","journal-title":"J Pharmacol Exp Ther"},{"key":"847_CR8","first-page":"RA5","volume":"10","author":"J Sun","year":"2004","unstructured":"Sun J, He ZG, Cheng G, Wang SJ, Hao XH, Zou MJ (2004) Multidrug resistance P-glycoprotein: crucial significance in drug disposition and interaction. Med Sci Monit 10:RA5\u2013RA14","journal-title":"Med Sci Monit"},{"key":"847_CR9","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2165\/00003088-200342090-00003","volume":"42","author":"M Niemi","year":"2003","unstructured":"Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT (2003) Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 42:819\u2013850","journal-title":"Clin Pharmacokinet"},{"key":"847_CR10","unstructured":"WHO (2006) Antiretroviral therapy of HIV infection in infants and children: towards universal access. Recommendations for a public health approach. Available from: http:\/\/www.who.int\/hiv\/pub\/guidelines\/paediatric020907.pdf . Accessed October 2009"},{"key":"847_CR11","unstructured":"CDC (2007) Table\u00a02. Recommendations for coadministering protease inhibitors and non-nucleoside reverse transcriptase inhibitors with RIFAMPIN. Available from: http:\/\/www.cdc.gov\/tb\/publications\/guidelines\/TB_HIV_Drugs\/Table2.htm . Accessed October 2009"},{"key":"847_CR12","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1128\/AAC.48.5.1553-1560.2004","volume":"48","author":"CJ Porte La","year":"2004","unstructured":"La Porte CJ, Colbers EP, Bertz R, Voncken DS, Wikstrom K, Boeree MJ, Koopmans PP, Hekster YA, Burger DM (2004) Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother 48:1553\u20131560","journal-title":"Antimicrob Agents Chemother"},{"key":"847_CR13","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2165\/00003088-200241140-00001","volume":"41","author":"JR King","year":"2002","unstructured":"King JR, Kimberlin DW, Aldrovandi GM, Acosta EP (2002) Antiretroviral pharmacokinetics in the paediatric population: a review. Clin Pharmacokinet 41:1115\u20131133","journal-title":"Clin Pharmacokinet"},{"key":"847_CR14","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1128\/AAC.48.4.1073-1081.2004","volume":"48","author":"SU Sankatsing","year":"2004","unstructured":"Sankatsing SU, Beijnen JH, Schinkel AH, Lange JM, Prins JM (2004) P-glycoprotein in human immunodeficiency virus type 1 infection and therapy. Antimicrob Agents Chemother 48:1073\u20131081","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"847_CR15","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1128\/AAC.00943-05","volume":"50","author":"V Jullien","year":"2006","unstructured":"Jullien V, Urien S, Hirt D, Delaugerre C, Rey E, Teglas JP, Vaz P, Rouzioux C, Chaix ML, Macassa E, Firtion G, Pons G, Blanche S, Tr\u00e9luyer JM (2006) Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18\u00a0years. Antimicrob Agents Chemother 50(11):3548\u20133555","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"847_CR16","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1128\/AAC.01374-08","volume":"53","author":"N Rakhmanina","year":"2009","unstructured":"Rakhmanina N, van den Anker J, Baghdassarian A, Soldin S, Williams K, Neely MN (2009) Population pharmacokinetics of lopinavir predict suboptimal therapeutic concentrations in treatment-experienced human immunodeficiency virus-infected children. Antimicrob Agents Chemother 53(6):2532\u20132538","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"847_CR17","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2165\/00003088-200847100-00005","volume":"47","author":"J Molt\u00f3","year":"2008","unstructured":"Molt\u00f3 J, Barbanoj MJ, Miranda C, Blanco A, Santos JR, Negredo E, Costa J, Domingo P, Clotet B, Valle M (2008) Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV-infected adults. Clin Pharmacokinet 47(10):681\u2013692","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"847_CR18","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1365-2125.2005.02455.x","volume":"60","author":"KM Crommentuyn","year":"2005","unstructured":"Crommentuyn KM, Kappelhoff BS, Mulder JW, Mairuhu AT, van Gorp EC, Meenhorst PL, Huitema AD, Beijnen JH (2005) Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients. Br J Clin Pharmacol 60(4):378\u2013389","journal-title":"Br J Clin Pharmacol"},{"key":"847_CR19","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/QAI.0b013e3181642257","volume":"47","author":"Y Ren","year":"2008","unstructured":"Ren Y, Nuttall JJ, Egbers C, Eley BS, Meyers TM, Smith PJ, Maartens G, McIlleron HM (2008) Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr 47:566\u2013569","journal-title":"J Acquir Immune Defic Syndr"},{"key":"847_CR20","volume-title":"NONMEM user's guide, NONMEM Project Group","author":"SL Beal","year":"1994","unstructured":"Beal SL, Sheiner LS (1994) NONMEM user's guide, NONMEM Project Group. University of California at San Francisco, San Francisco"},{"key":"847_CR21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0169-2607(98)00067-4","volume":"58","author":"EN Jonsson","year":"1999","unstructured":"Jonsson EN, Karlsson MO (1999) Xpose-an S-PLUS based population pharmacokinetic\/pharmacodynamic model building aid for NONMEM. Comput Meth Programs Biomed 58:51\u201364","journal-title":"Comput Meth Programs Biomed"},{"key":"847_CR22","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/j.1552-4604.1997.tb04326.x","volume":"37","author":"EI Ette","year":"1997","unstructured":"Ette EI (1997) Stability and performance of a population pharmacokinetic model. J Clin Pharmacol 37:486\u2013495","journal-title":"J Clin Pharmacol"},{"key":"847_CR23","unstructured":"Keulen (2006) Recommendations for performing TDM of antiretroviral agents. Available from: http:\/\/hivpharmacology.production.tdclighthouse.com\/content.cfm?lang=1&id=573&id2=639&ch=4&cid=639 . Accessed October 2009"},{"key":"847_CR24","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s002280050545","volume":"54","author":"RJ Gass","year":"1998","unstructured":"Gass RJ, Gal J, Fogle PW, Detmar-Hanna D, Gerber JG (1998) Neither dapsone hydroxylation nor cortisol 6beta-hydroxylation detects the inhibition of CYP3A4 by HIV-1 protease inhibitors. Eur J Clin Pharmacol 54:741\u2013747","journal-title":"Eur J Clin Pharmacol"},{"key":"847_CR25","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.1365-2125.1998.00749.x","volume":"46","author":"D Ouellet","year":"1998","unstructured":"Ouellet D, Hsu A, Qian J, Locke CS, Eason CJ, Cavanaugh JH, Leonard JM, Granneman GR (1998) Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br J Clin Pharmacol 46:111\u2013116","journal-title":"Br J Clin Pharmacol"},{"key":"847_CR26","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1592\/phco.20.1.93.34654","volume":"20","author":"SM Geletko","year":"2000","unstructured":"Geletko SM, Erickson AD (2000) Decreased methadone effect after ritonavir initiation. Pharmacotherapy 20:93\u201394","journal-title":"Pharmacotherapy"},{"key":"847_CR27","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1124\/dmd.30.7.795","volume":"30","author":"G Luo","year":"2002","unstructured":"+Luo G, Cunningham M, Kim S, Burn T, Lin J, Sinz M, Hamilton G, Rizzo C, Jolley S, Gilbert D, Downey A, Mudra D, Graham R, Carroll K, Xie J, Madan A, Parkinson A, Christ D, Selling B, LeCluyse E, Gan LS (2002) CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 30:795\u2013804","journal-title":"Drug Metab Dispos"},{"key":"847_CR28","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/ajcn\/78.2.319","volume":"78","author":"NI Paton","year":"2003","unstructured":"Paton NI, Ng YM, Chee CB, Persaud C, Jackson AA (2003) Effects of tuberculosis and HIV infection on whole-body protein metabolism during feeding, measured by the [15N]glycine method. Am J Clin Nutr 78:319\u2013325","journal-title":"Am J Clin Nutr"},{"key":"847_CR29","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.nut.2005.06.009","volume":"22","author":"NI Paton","year":"2006","unstructured":"Paton NI, Ng YM (2006) Body composition studies in patients with wasting associated with tuberculosis. Nutrition 22:245\u2013251","journal-title":"Nutrition"},{"key":"847_CR30","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1365-2125.2004.02241.x","volume":"59","author":"BS Kappelhoff","year":"2005","unstructured":"Kappelhoff BS, Huitema AD, Crommentuyn KM, Mulder JW, Meenhorst PL, van Gorp EC, Mairuhu AT, Beijnen JH (2005) Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients. Br J Clin Pharmacol 59:174\u2013182","journal-title":"Br J Clin Pharmacol"},{"key":"847_CR31","unstructured":"Ritonavir (Norvir) [product monograph]. Abbott Laboratories"},{"key":"847_CR32","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1080\/00498250701670945","volume":"37","author":"K Venkatakrishnan","year":"2007","unstructured":"Venkatakrishnan K, Obach RS, Rostami-Hodjegan A (2007) Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug-drug interaction risk assessment. Xenobiotica 37:1225\u20131256","journal-title":"Xenobiotica"},{"key":"847_CR33","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.clpt.2005.11.009","volume":"79","author":"KE Culm-Merdek","year":"2006","unstructured":"Culm-Merdek KE, von Moltke LL, Gan L, Horan KA, Reynolds R, Harmatz JS, Court MH, Greenblatt DJ (2006) Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir. Clin Pharmacol Ther 79:243\u2013254","journal-title":"Clin Pharmacol Ther"},{"key":"847_CR34","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1177\/135965350701200405","volume":"12","author":"G Verweel","year":"2007","unstructured":"Verweel G, Burger DM, Sheehan NL, Bergshoeff AS, Warris A, van der Knaap LC, Driessen G, de Groot R, Hartwig NG (2007) Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2\u00a0years and below. Antivir Ther 12:453\u2013458","journal-title":"Antivir Ther"},{"key":"847_CR35","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/QAD.0b013e3282f2be1d","volume":"22","author":"EG Chadwick","year":"2008","unstructured":"Chadwick EG, Capparelli EV, Yogev R, Pinto JA, Robbins B, Rodman JH, Chen J, Palumbo P, Serchuck L, Smith E, Hughes M, P1030 team (2008) Pharmacokinetics, safety and efficacy of lopinavir\/ritonavir in infants less than 6\u00a0months of age: 24\u00a0week results. AIDS 22:249\u2013255","journal-title":"AIDS"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-010-0847-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-010-0847-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-010-0847-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T23:51:54Z","timestamp":1740181914000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-010-0847-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,16]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["847"],"URL":"https:\/\/doi.org\/10.1007\/s00228-010-0847-9","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,16]]}}}